XLO Insider Trading - Xilio Therapeutics, Inc.

Deler fremragende	5,782,511 shares
Insideraktier	2.123.099 shares
Insider ejerskab	36,72 %
Total Insiders	49

Insider-stemningsscore

Insider Sentiment Score viser, at virksomhederne bliver købt af virksomheders insidere.

Det er resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af insider-akkumulering. Scoringsmodellen bruger en kombination af nettoantallet af insidere, der har købt de foregående 90 dage, det samlede antal aktier købt som en procentdel af float og det samlede antal aktier ejet af insidere. Tallet går fra 0 til 100, hvor højere tal indikerer et højere niveau af akkumulering for sine jævnaldrende, og 50 er gennemsnittet.

Opdateringsfrekvens: Dagligt

Se Insiders Top Picks, som giver en liste over virksomheder med den højeste insider-akkumulering.

Se Højest rangerende aktier

Officers sentiment score

Officer Sentiment Score finder virksomheder, der bliver købt af Corporate Officers.

Per definition er Corporate Officers Corporate Insiders, men i modsætning til nogle af de andre Insiders (10 % aktionærer og bestyrelsesmedlemmer), arbejder officerer for virksomheden på daglig basis, og de bruger deres egne penge, når de handler . (10 % aktionærer og bestyrelsesmedlemmer er ofte fondsforvaltere, der administrerer andres penge.) Som sådan er insiderhandler foretaget af embedsmænd meget mere betydningsfulde og bør behandles passende.

Ligesom Insider Sentiment Score er Officer Sentiment Score resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af officerakkumulering.

Opdateringsfrekvens: Dagligt

Se Insiders Top Picks, som giver en liste over virksomheder med højeste insider-stemning.

Se Højest rangerende aktier

Nøgle Insider Metrics

Dette kort viser, hvordan virksomheden rangerer langs forskellige insider-metrics. Percentilrangen viser, hvordan denne virksomhed sammenligner sig med andre virksomheder på de amerikanske markeder. Højere placeringer er tegn på bedre situationer.

For eksempel er det generelt accepteret, at insider-køb er en positiv indikator, så virksomheder med flere insider-køb vil rangere højere end virksomheder med mindre insider-køb (eller endda insider-salg).

Netto antal insidere, der køber (rang)

1 ( )

350 out of 10986

Netto antal insidere, der køber, er det samlede antal insiders, der køber minus det samlede antal insiders, der har solgt inden for de sidste 90 dage. Percentilrangen vises her (spænder fra 0 til 100%).

Procent af float købt af insidere (rangering)

0.145% ( )

240 out of 10856

Procent af float købt af insidere er det samlede antal aktier købt af insidere minus det samlede antal aktier solgt af insidere inden for de sidste 90 dage, divideret med den samlede float og ganget med 100.

Insiderhandelsdiagram

Xilio Therapeutics, Inc. insiderhandler er vist i følgende diagram. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Generelt er det generelt ulovligt for insidere at foretage handler i deres virksomheder baseret på væsentlige, ikke-offentlige oplysninger. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4.

Insiderliste og lønsomhedsmålinger

Denne tabel viser listen over kendte insidere og genereres automatisk fra arkiveringer, der er videregivet til SEC. Ud over navnene, den seneste titel og direktør, officer eller 10 % ejerbetegnelse giver vi de seneste offentliggjorte besiddelser. Derudover giver vi, når det er muligt, den historiske handelspræstation for insideren. Den historiske handelspræstation er et vægtet gennemsnit af præstationen af faktiske købstransaktioner på det åbne marked foretaget af insideren. For mere information om, hvordan dette beregnes, se dette YouTube-webinar.

See our leaderboard of most profitable insider traders.

Insider	Aktier Ejet	Dele Justeret
Alexandria Venture Investments, LLC 10% Owner - [10%]	166.423	11.887
Atlas Venture Associates Opportunity I, L.P. 10% Owner - [10%]	26.315	52.468
Atlas Venture Associates Opportunity I, LLC 10% Owner - [10%]	26.315	52.468
Atlas Venture Associates XI, L.P. 10% Owner - [10%]	26.315	52.468
Atlas Venture Associates XI, LLC 10% Owner - [10%]	26.315	52.468
Atlas Venture Fund XI, L.P. 10% Owner - [10%]	734.546	52.468
Atlas Venture Opportunity Fund I, L.P. 10% Owner - [10%]	735.942	52.468
Bay City Capital Llc 10% Owner - [10%]	1.129.490	80.678
BCIP Life Sciences Associates, LP 10% Owner - [10%]	2.805.413	200.387
BCLS II Investco, LP 10% Owner - [10%]	2.805.413	200.387
BCLS II Investo (GP), LLC 10% Owner - [10%]	2.805.413	200.387
Bain Capital Life Sciences Fund II, L.P. 10% Owner - [10%]	2.805.413	200.387
Bain Capital Life Sciences Investors II, LLC 10% Owner - [10%]	2.805.413	200.387
Bain Capital Life Sciences Investors, LLC 10% Owner - [10%]	2.805.413	200.387
Brennan Kevin M. SVP, FINANCE AND ACCOUNTING - [O]	6.371	455
Timothy P Clackson 10% Owner - [10%]	70.888	5.063

Insider	Aktier Ejet	Dele Justeret
Yekaterina Chudnovsky 10% Owner - [10%]	7.000.000	500.000
Paul J Clancy	65.528
Management Co Deerfield 10% Owner - [10%]	1.143.972	81.712
Deerfield Partners, L.p. 10% Owner - [10%]	1.143.972	81.712
Deerfield Mgmt L.P. 10% Owner - [10%]	1.143.972	81.712
Deerfield Mgmt V, L.P. 10% Owner - [10%]	1.143.972	81.712
Edward C English Principal Accounting Officer - [O]	6.002	429
of Ulrich Rodeck Estate 10% Owner - [10%]	100.080	7.149
Ltd FIL -	218.705	15.622
FMR LLC / Fidelity Management & Research -	4.465	319
James E Flynn 10% Owner - [10%]	1.143.972	81.712
Four Pines Master Fund LP 10% Owner - [10%]	1.256.472	89.748
Christopher James Frankenfield Chief Financial Officer - [O]	24.766	1.769
Gilead Sciences Inc 10% Owner - [10%]	9.105.451	650.389
Salvatore Giovine	49.500
Rachel Humphrey Director - [D]	9.444	675

Insider	Aktier Ejet	Dele Justeret
Huber Martin H. Jr.	65.000
Katarina Luptakova CHIEF MEDICAL OFFICER - [O]	33.250	2.375
KGaA Merck 10% Owner - [10%]	680.825	48.630
Michael Jay Ross	26.400
RiverVest Venture Fund IV, L.P. 10% Owner - [10%]	1.441.444	102.960
Rock Springs Capital LLC 10% Owner - [10%]	1.256.472	89.748
Rock Springs Capital Management LP 10% Owner - [10%]	1.256.472	89.748
Rock Springs Capital Master Fund LP 10% Owner - [10%]	1.256.472	89.748
Rene Russo PRESIDENT AND CEO, Director - [D] [O]	325.422	23.244
Sv7 (imf) Gp Llp 10% Owner - [10%]	1.613.632	115.259
SV7 Impact Medicine Fund LP 10% Owner - [10%]	1.613.632	115.259
James Samuel Shannon Director - [D]	10.000	10.000
Pharmaceutical Co Ltd Takeda 10% Owner - [10%]	1.475.121	105.366
Simon M Tomlinson 10% Owner - [10%]	131.117	9.366
Takeda Ventures, Inc. 10% Owner - [10%]	1.475.121	105.366
John Charles Williams 10% Owner - [10%]	100.080	7.149
Yuan Xu	26.400

Report errors via our new Insider Auditing Tool

Track Records af insiderkøb - Kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i XLO / Xilio Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Maks	Pris kl Maks	Maks Fortjeneste ($)	Maks. afkast (%)
2026-03-26	Shannon James Samuel	5.000	8,7900	5.000	8,7900	43.950	13	8.6900	-500	-1,14
2025-06-17	Shannon James Samuel	25.000	0,6886	1.786	9,6404	17.215
2025-06-16	Shannon James Samuel	45.000	0,6860	3.214	9,6040	30.870
2025-06-16	Russo Rene	36.289	0,6801	2.592	9,5214	24.680
2024-12-18	GILEAD SCIENCES INC	1.759.978	1,0400	125.713	14,5600	1.830.377
2024-04-02	GILEAD SCIENCES INC	485.250	0,7600	34.661	10,6400	368.790
2021-12-10	Bain Capital Life Sciences Investors, LLC	21.812	9,5619	1.558	133,8666	208.564
2021-12-10	Bain Capital Life Sciences Investors, LLC	3.188	10,2378	228	143,3292	32.638
2021-12-09	Bain Capital Life Sciences Investors, LLC	4.011	9,8442	286	137,8188	39.485

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

XLO / Xilio Therapeutics, Inc. Insider Trades

Track Records af insidersalg - Kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i XLO / Xilio Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Min	Pris kl Min	Max tab Undgået ($)	Max tab Undgået (%)
2024-02-08	Atlas Venture Fund XI, L.P.	267	0,6400	19	8,9600	171	14	0.5500	-160	-93,85
2024-02-08	Atlas Venture Fund XI, L.P.	733	0,6400	52	8,9600	469
2024-01-12	Atlas Venture Fund XI, L.P.	560	0,8300	40	11,6200	465
2024-01-12	Atlas Venture Fund XI, L.P.	1.540	0,8300	110	11,6200	1.278
2024-01-11	Atlas Venture Fund XI, L.P.	1.566	0,8700	112	12,1800	1.362
2024-01-11	Atlas Venture Fund XI, L.P.	569	0,8700	41	12,1800	495

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Transaktionshistorik

Klik på linkikonet for at se den fulde transaktionshistorik. Transaktioner, der rapporteres som en del af en automatisk handelsplan 10b5-1, vil have et X i kolonnen markeret 10b-5.

Fil Dato	Handle Dato	Form	Insider	Ticker	Sikkerhedstitel	Kode	Direkte	Dyrke motion Pris	Enhed Pris	Enheder Ændret	Værdi Ændret (1K)	Tilbage Muligheder	Tilbage Aktier
2026-03-30	2026-03-26	4	Shannon James Samuel	XLO	Common Stock	P - Purchase	D		8,7900	5.000	44		10.000
2026-01-05	2026-01-01	4	Russo Rene	XLO	Common Stock	M - Exercise	D			44.250			325.422
2026-01-05	2026-01-02	4	Frankenfield Christopher James	XLO	Common Stock	S - Sale	D		0,6432	-7.030	-5		24.766
2026-01-05	2026-01-01	4	Frankenfield Christopher James	XLO	Common Stock	M - Exercise	D			19.375			31.796
2026-01-05	2026-01-02	4	Brennan Kevin M.	XLO	Common Stock	S - Sale	D		0,6432	-1.826	-1		6.371
2026-01-05	2026-01-01	4	Brennan Kevin M.	XLO	Common Stock	M - Exercise	D			5.000			8.197
2026-01-05	2026-01-01	4	Luptakova Katarina	XLO	Common Stock	M - Exercise	D			16.625			33.250
2025-06-18	2025-06-16	4	Russo Rene	XLO	Common Stock	P - Purchase	D		0,6801	36.289	25		281.172
2025-06-18	2025-06-17	4	Shannon James Samuel	XLO	Common Stock	P - Purchase	D		0,6886	25.000	17		70.000
2025-06-18	2025-06-16	4	Shannon James Samuel	XLO	Common Stock	P - Purchase	D		0,6860	45.000	31		45.000
2025-01-03	2025-01-01	4	Russo Rene	XLO	Common Stock	M - Exercise	D			44.250			244.883
2025-01-03	2025-01-02	4	Brennan Kevin M.	XLO	Common stock	S - Sale	D		0,9837	-1.803	-2		3.197
2025-01-03	2025-01-01	4	Brennan Kevin M.	XLO	Common Stock	M - Exercise	D			5.000			5.000
2025-01-03	2025-01-02	4	Frankenfield Christopher James	XLO	Common stock	S - Sale	D		0,9837	-6.954	-7		12.421
2025-01-03	2025-01-01	4	Frankenfield Christopher James	XLO	Common Stock	M - Exercise	D			19.375			19.375
2025-01-03	2025-01-01	4	Luptakova Katarina	XLO	Common Stock	M - Exercise	D			16.625			16.625
2024-12-19	2024-12-18	4	GILEAD SCIENCES INC	XLO	Common Stock	P - Purchase	D		1,0400	1.759.978	1.830		9.105.451
2024-09-27		3	Chudnovsky Yekaterina Held by GKCC, LLC	XLO	Common Stock		I						7.000.000
2024-04-03	2024-04-02	4	GILEAD SCIENCES INC	XLO	Common Stock	P - Purchase	D		0,7600	485.250	369		7.345.473
2024-04-03		3	GILEAD SCIENCES INC	XLO	Common Stock		D						6.860.223
2024-02-09	2024-02-08	4	Atlas Venture Fund XI, L.P.	XLO	Common Stock	S - Sale	I		0,6400	-267	-0		734.546
2024-02-09	2024-02-08	4	Atlas Venture Fund XI, L.P.	XLO	Common Stock	S - Sale	D		0,6400	-733	-0		2.019.563
2024-01-16	2024-01-12	4	Atlas Venture Fund XI, L.P.	XLO	Common Stock	S - Sale	I		0,8300	-560	-0		734.813
2024-01-16	2024-01-12	4	Atlas Venture Fund XI, L.P.	XLO	Common Stock	S - Sale	D		0,8300	-1.540	-1		2.020.296
2024-01-16	2024-01-11	4	Atlas Venture Fund XI, L.P.	XLO	Common Stock	S - Sale	I		0,8700	-569	-0		735.373
2024-01-16	2024-01-11	4	Atlas Venture Fund XI, L.P.	XLO	Common Stock	S - Sale	D		0,8700	-1.566	-1		2.021.836
2022-11-16		3	English Edward C	XLO	Common Stock		D						6.002
2022-02-24	2022-02-22	4	Russo Rene	XLO	Stock Option (right to buy)	A - Award	D	12,66		150.000		150.000
2022-02-24	2022-02-22	4	Giovine Salvatore	XLO	Stock Option (right to buy)	A - Award	D	12,66		49.500		49.500
2022-02-24	2022-02-22	4	Huber Martin H. Jr.	XLO	Stock Option (right to buy)	A - Award	D	12,66		65.000		65.000
2022-01-06	2022-01-04	4	Xu Yuan	XLO	Stock Option (right to buy)	A - Award	D	15,92		26.400		26.400
2022-01-04	2021-12-22	4/A	Russo Rene	XLO	Stock Option (right to buy)	A - Award	D	13,83		100.000		100.000
2021-12-23	2021-12-22	4	Russo Rene	XLO	Stock Option (right to buy)	A - Award	D	13,83		100.000		100.000
2021-12-10	2021-12-10	4	Bain Capital Life Sciences Investors, LLC See footnotes	XLO	Common Stock	P - Purchase	I		10,2378	3.188	33		2.805.413
2021-12-10	2021-12-10	4	Bain Capital Life Sciences Investors, LLC See footnotes	XLO	Common Stock	P - Purchase	I		9,5619	21.812	209		2.802.225
2021-12-10	2021-12-09	4	Bain Capital Life Sciences Investors, LLC See footnotes	XLO	Common Stock	P - Purchase	I		9,8442	4.011	39		2.780.413
2021-12-10	2021-12-08	4	Bain Capital Life Sciences Investors, LLC See footnotes	XLO	Common Stock	P - Purchase	I		9,6206	13.458	129		2.776.402
2021-11-05		3	BCIP Life Sciences Associates, LP See footnotes	XLO	Common Stock		I						2.762.944
2021-11-03	2021-10-26	4/A	SV7 Impact Medicine Fund LP	XLO	Series C Convertible Preferred Stock	C - Conversion	D			-2.874.595		0
2021-11-03	2021-10-26	4/A	SV7 Impact Medicine Fund LP	XLO	Series C Convertible Preferred Stock	C - Conversion	I			-2.874.595		0
2021-11-03	2021-10-26	4/A	SV7 Impact Medicine Fund LP	XLO	Series B Convertible Preferred Stock	C - Conversion	D			-9.486.166		0
2021-11-03	2021-10-26	4/A	SV7 Impact Medicine Fund LP	XLO	Series B Convertible Preferred Stock	C - Conversion	I			-9.486.166		0
2021-11-03	2021-10-26	4/A	SV7 Impact Medicine Fund LP	XLO	Common Stock	P - Purchase	I		16,0000	312.500	5.000		1.613.632
2021-11-03	2021-10-26	4/A	SV7 Impact Medicine Fund LP	XLO	Common Stock	P - Purchase	D		16,0000	312.500	5.000		1.613.632
2021-11-03	2021-10-26	4/A	SV7 Impact Medicine Fund LP	XLO	Common Stock	C - Conversion	I			302.588			1.301.132
2021-11-03	2021-10-26	4/A	SV7 Impact Medicine Fund LP	XLO	Common Stock	C - Conversion	D			302.588			1.301.132
2021-11-03	2021-10-26	4/A	SV7 Impact Medicine Fund LP	XLO	Common Stock	C - Conversion	D			998.544			998.544
2021-11-03	2021-10-26	4/A	SV7 Impact Medicine Fund LP	XLO	Common Stock	C - Conversion	I			998.544			998.544
2021-10-28	2021-10-26	4	Flynn James E Through Deerfield Private Design Fund V, L.P.	XLO	Series C Preferred Stock	C - Conversion	I			-7.186.489		0
2021-10-28	2021-10-26	4	Flynn James E Through Deerfield Partners, L.P.	XLO	Series C Preferred Stock	C - Conversion	I			-7.186.489		0
2021-10-28	2021-10-26	4	Flynn James E Through Deerfield Private Design Fund V, L.P.	XLO	Common Stock	P - Purchase	I		16,0000	387.500	6.200		1.143.972
2021-10-28	2021-10-26	4	Flynn James E Through Deerfield Partners, L.P.	XLO	Common Stock	P - Purchase	I		16,0000	387.500	6.200		1.143.972
2021-10-28	2021-10-26	4	Flynn James E Through Deerfield Private Design Fund V, L.P.	XLO	Common Stock	C - Conversion	I			756.472			756.472
2021-10-28	2021-10-26	4	Flynn James E Through Deerfield Partners, L.P.	XLO	Common Stock	C - Conversion	I			756.472			756.472
2021-10-28	2021-10-26	4	FIL Ltd Eight Roads Investments	XLO	Series B Preferred Stock	C - Conversion	I			-2.077.698		0
2021-10-28	2021-10-26	4	FIL Ltd Eight Roads Investments	XLO	Common Stock	C - Conversion	I			218.705			218.705
2021-10-28	2021-10-26	4	FMR LLC / Fidelity Management & Research F-Prime Capital Partners Healthcare Advisors Fund IV LP	XLO	Series B Preferred Stock	C - Conversion	I			-42.421		0
2021-10-28	2021-10-26	4	FMR LLC / Fidelity Management & Research Impresa Fund III Limited Partnership	XLO	Series B Preferred Stock	C - Conversion	I			-3.536.046		0
2021-10-28	2021-10-26	4	FMR LLC / Fidelity Management & Research F-Prime Capital Partners Healthcare Fund IV LP	XLO	Series B Preferred Stock	C - Conversion	I			-272.687		0
2021-10-28	2021-10-26	4	FMR LLC / Fidelity Management & Research F-Prime Capital Partners Healthcare Fund IV LP	XLO	Series A-1 Preferred Stock	C - Conversion	I			-6.521.739		0
2021-10-28	2021-10-26	4	FMR LLC / Fidelity Management & Research F-Prime Capital Partners Healthcare Fund IV LP	XLO	Series A Preferred Stock	C - Conversion	I			-7.500.000		0
2021-10-28	2021-10-26	4	FMR LLC / Fidelity Management & Research F-Prime Capital Partners Healthcare Advisors Fund IV LP	XLO	Common Stock	C - Conversion	I			4.465			4.465
2021-10-28	2021-10-26	4	FMR LLC / Fidelity Management & Research Impresa Fund III Limited Partnership	XLO	Common Stock	C - Conversion	I			372.215			372.215
2021-10-28	2021-10-26	4	FMR LLC / Fidelity Management & Research F-Prime Capital Partners Healthcare Fund IV LP	XLO	Common Stock	C - Conversion	I			28.703			1.530.990
2021-10-28	2021-10-26	4	FMR LLC / Fidelity Management & Research F-Prime Capital Partners Healthcare Fund IV LP	XLO	Common Stock	C - Conversion	I			686.499			1.502.287
2021-10-28	2021-10-26	4	FMR LLC / Fidelity Management & Research F-Prime Capital Partners Healthcare Fund IV LP	XLO	Common Stock	C - Conversion	I			789.473			815.788
2021-10-28	2021-10-26	4	SV7 Impact Medicine Fund LP	XLO	Series C Convertible Preferred Stock	C - Conversion	D			-2.874.595		0
2021-10-28	2021-10-26	4	SV7 Impact Medicine Fund LP	XLO	Series C Convertible Preferred Stock	C - Conversion	I			-2.874.595		0
2021-10-28	2021-10-26	4	SV7 Impact Medicine Fund LP	XLO	Series B Convertible Preferred Stock	C - Conversion	I			-9.486.166		0
2021-10-28	2021-10-26	4	SV7 Impact Medicine Fund LP	XLO	Series B Convertible Preferred Stock	C - Conversion	D			-9.486.166		0
2021-10-28	2021-10-26	4	SV7 Impact Medicine Fund LP	XLO	Common Stock	C - Conversion	D			302.588			1.301.132
2021-10-28	2021-10-26	4	SV7 Impact Medicine Fund LP	XLO	Common Stock	C - Conversion	I			302.588			1.301.132
2021-10-28	2021-10-26	4	SV7 Impact Medicine Fund LP	XLO	Common Stock	C - Conversion	D			998.544			998.544
2021-10-28	2021-10-26	4	SV7 Impact Medicine Fund LP	XLO	Common Stock	C - Conversion	I			998.544			998.544
2021-10-26	2021-10-26	4	TAKEDA PHARMACEUTICAL CO LTD See explanation	XLO	Series C Preferred Stock	C - Conversion	I			-226.941		0
2021-10-26	2021-10-26	4	TAKEDA PHARMACEUTICAL CO LTD See explanation	XLO	Series B Preferred Stock	C - Conversion	I			-1.248.180		0
2021-10-26	2021-10-26	4	TAKEDA PHARMACEUTICAL CO LTD See explanation	XLO	Common Stock	C - Conversion	I			1.475.121			1.475.121
2021-10-26	2021-10-26	4	RiverVest Venture Fund IV, L.P. See Footnotes	XLO	Series B Preferred Stock	C - Conversion	I			-359.324		0
2021-10-26	2021-10-26	4	RiverVest Venture Fund IV, L.P. See Footnotes	XLO	Series B Preferred Stock	C - Conversion	I			-832.120		0
2021-10-26	2021-10-26	4	RiverVest Venture Fund IV, L.P. See Footnotes	XLO	Common Stock	P - Purchase	I		16,0000	250.000	4.000		1.441.444
2021-10-26	2021-10-26	4	RiverVest Venture Fund IV, L.P. See Footnotes	XLO	Common Stock	C - Conversion	I			359.324			1.191.444
2021-10-26	2021-10-26	4	RiverVest Venture Fund IV, L.P. See Footnotes	XLO	Common Stock	C - Conversion	I			832.120			832.120
2021-10-26	2021-10-26	4	Merck KGaA	XLO	Series C Preferred Srock	C - Conversion	I			-2.515.271		0
2021-10-26	2021-10-26	4	Merck KGaA	XLO	Series B Preferred Stock	C - Conversion	I			-3.952.568		0
2021-10-26	2021-10-26	4	Merck KGaA	XLO	Common Stock	C - Conversion	I			264.765			680.825
2021-10-26	2021-10-26	4	Merck KGaA	XLO	Common Stock	C - Conversion	I			416.060			416.060
2021-10-26	2021-10-26	4	Rock Springs Capital Management LP	XLO	Series C Preferred Stock	C - Conversion	I			-1.437.297		0
2021-10-26	2021-10-26	4	Rock Springs Capital Management LP	XLO	Series C Preferred Stock	C - Conversion	I			-7.186.490		0
2021-10-26	2021-10-26	4	Rock Springs Capital Management LP	XLO	Common Stock	P - Purchase	I		16,0000	500.000	8.000		1.256.472
2021-10-26	2021-10-26	4	Rock Springs Capital Management LP	XLO	Common Stock	C - Conversion	I			151.294			151.294
2021-10-26	2021-10-26	4	Rock Springs Capital Management LP	XLO	Common Stock	C - Conversion	I			756.472			756.472
2021-10-26	2021-10-26	4	BAY CITY CAPITAL LLC See footnotes	XLO	Series C Preferred Stock	C - Conversion	I			-1.437.297		0
2021-10-26	2021-10-26	4	BAY CITY CAPITAL LLC See footnotes	XLO	Series B Preferred Stock	C - Conversion	I			-6.324.110		0
2021-10-26	2021-10-26	4	BAY CITY CAPITAL LLC See footnotes	XLO	Common Stock	P - Purchase	I		16,0000	312.500	5.000		1.129.490
2021-10-26	2021-10-26	4	BAY CITY CAPITAL LLC See footnotes	XLO	Common Stock	C - Conversion	I			151.294			816.990
2021-10-26	2021-10-26	4	BAY CITY CAPITAL LLC See footnotes	XLO	Common Stock	C - Conversion	I			665.696			665.696
2021-10-26	2021-10-26	4	Clancy Paul J	XLO	Stock Option (right to buy)	A - Award	D	5,89		65.528		65.528
2021-10-26	2021-10-26	4	Clancy Paul J	XLO	Stock Option (right to buy)	A - Award	D	5,51		44.033		44.033
2021-10-26	2021-10-26	4	Atlas Venture Fund XI, L.P.	XLO	Series C Preferred Stock	C - Conversion	I			-5.210.204		0
2021-10-26	2021-10-26	4	Atlas Venture Fund XI, L.P.	XLO	Series B Preferred Stock	C - Conversion	I			-5.928.852		0
2021-10-26	2021-10-26	4	Atlas Venture Fund XI, L.P.	XLO	Series A1 Preferred Stock	C - Conversion	I			-13.043.477		0
2021-10-26	2021-10-26	4	Atlas Venture Fund XI, L.P.	XLO	Common Stock	P - Purchase	I		16,0000	187.500	3.000		735.942
2021-10-26	2021-10-26	4	Atlas Venture Fund XI, L.P.	XLO	Common Stock	C - Conversion	I			548.442			548.442
2021-10-26	2021-10-26	4	Atlas Venture Fund XI, L.P.	XLO	Common Stock	C - Conversion	I			624.089			2.023.402
2021-10-26	2021-10-26	4	Atlas Venture Fund XI, L.P.	XLO	Common Stock	C - Conversion	I			1.372.998			1.399.313
2021-10-26	2021-10-26	4	Alexandria Venture Investments, LLC	XLO	Series B convertible preferred stock	C - Conversion	D			-1.581.026		0
2021-10-26	2021-10-26	4	Alexandria Venture Investments, LLC	XLO	Common stock	C - Conversion	D			166.423			166.423
2021-10-25	2021-10-21	4	Russo Rene	XLO	Stock Option (right to buy)	A - Award	D	16,00		50.041		50.041
2021-10-25	2021-10-21	4	Huber Martin H. Jr.	XLO	Stock Option (right to buy)	A - Award	D	16,00		157.058		157.058
2021-10-25	2021-10-21	4	ROSS MICHAEL JAY	XLO	Stock Option (right to buy)	A - Award	D	16,00		26.400		26.400
2021-10-25	2021-10-21	4	Giovine Salvatore	XLO	Stock Option (right to buy)	A - Award	D	16,00		28.755		28.755
2021-10-22		3	Williams John Charles	XLO	Common Stock		D						100.080
2021-10-21		3	Estate of Ulrich Rodeck	XLO	Common Stock		D						100.080
2021-10-21		3	TOMLINSON SIMON M	XLO	Common Stock		D						131.117
2021-10-21		3	CLACKSON TIMOTHY P The Timothy P. Clackson Irrevocable GST Trust of 2020	XLO	Common Stock		I						70.888
2021-10-21		3	CLACKSON TIMOTHY P	XLO	Common Stock		D						20.068
2021-10-21		3	Atlas Venture Associates Opportunity I, LLC	XLO	Common Stock		I						26.315
2021-10-21		3	FMR LLC / Fidelity Management & Research F-Prime Capital Partners Healthcare Fund IV LP	XLO	Common Stock		I						26.315
2021-10-21		3	Russo Rene	XLO	Common Stock		D						200.633
2021-10-21		3	HUMPHREY RACHEL	XLO	Common Stock		D						9.444

Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer

Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer

Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)

Konvertering af derivat

Salg eller overførsel af værdipapirer tilbage til virksomheden

Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet

Gave af værdipapirer af eller til insideren

Aktieswaps og lignende sikringstransaktioner

Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)

En transaktion rapporteret frivilligt på formular 4

Andet (ledsaget af en fodnote, der beskriver transaktionen)

XLO / Xilio Therapeutics, Inc. - Insider Trading and Ownership Report - SEC Form 3, 4, 5